ClinicalTrials.gg
CompletedNCT06415279Updated Jun 15, 2026Results posted

A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients

A Phase 4 interventional study of Winlevi (clascoterone) 1% cream in Acne Vulgaris, sponsored by Sun Pharmaceutical Industries Limited. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
12th of 19
40 · median 50
Started
2024
with 4 others
Phase 4
7 of 19
1 open now
Registered
11th of 19
by date
Lead sponsor
6 of 19
Sun Pharmaceutical Industries Limited

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 12th largest by enrollment, is one of 5 that started in 2024, is one of 7 in phase 4, and was the 11th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

The etiology of acne is heavily dependent on the production of sebum by the sebaceous glands that results in the growth of the bacteria c. acnes. If no sebum is present, there is no nutritional source for the c. acnes, the bacteria die, and acne resolves. An FDA approved acne medication consisting of clascoterone cream 1% is believed to effectively treat acne due to a decrease in sebum production. This mechanism of action has been postulated based on efficacy observed in the phase III trials that lead to its approval. This research aims to demonstrate the effect of clascoterone cream 1% in sebum reduction.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females 12+ years of age.
  2. Subjects with mild to moderate acne.
  3. Subjects must possess 10-100 total non-inflammatory lesions (open comedones and closed comedones), 10-50 total inflammatory lesions, no cysts, and up to 2 nodules (if deemed appropriate by the PI) on the face.
  4. Subjects with all Fitzpatrick skin types I-VI.
  5. Subjects who agree to use only the study products for acne treatment. No other medicated cleansers or moisturizers or acne treatments of any kind are allowed.
  6. Subjects agree not to introduce any new colored cosmetics or skin care products while participating in the study (lipsticks, eye shadows, facial foundations, blush, powder, cleansers, moisturizers).
  7. Subjects agree to arrive at all visits with a clean face, having washed his/her face and removed all facial and eye makeup products within 2 hours to 4 hours prior to the visit and is not to use/apply any topical facial product(s) until the visit is completed.
  8. No known medical conditions that, in the investigator's opinion, may interfere with study participation.
  9. Women of must be willing to use a form of during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g., condom and spermicide) and abstinence.
  10. Subjects are dependable and able to follow directions and willing to comply with the schedule of visits.
  11. Subjects in generally good physical and mental health.
  12. Able to read, write, speak, and understand English
  13. Individual (and/or his/her legally acceptable representative, as applicable) has signed the Consent for Photograph Release and ICD (and/or Assent Document, as applicable) including Health Insurance Portability and Accountability Act (HIPAA) disclosure.
  14. Subject must avoid sun exposure, or use sunscreen if sun exposure is unavoidable.
  15. Subject must avoid professional or facial spa procedures during the study.

Exclusion criteria

Exclusion Criteria:

  1. Any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics, except for the study condition of acne.
  2. Subjects who are not willing to use the assigned study product to their face as instructed.
  3. Subjects who have acne nodules/cysts representative of severe acne.
  4. Subjects who are currently using, planning to use during the study or has used any of the following in the specified time range (based on subject report):

    • 1 month prior to Visit 1: Prescription (oral or topically applied on the face) antibiotics, inhaled (except those prescribed for allergies), or hormones (pre- or hormone-replacement therapy; insulin, etc.), or other medications that could make skin more sensitive or have an effect on the skin, as determined by the PI or designee. Oral are acceptable.
    • 1 month prior to Visit 1: Prescription medication for acne (e.g. doxycycline, minocycline, clindamycin, sulfamethoxazole and trimethoprim [Bactrim], tetracycline, erythromycin, azithromycin, or Vibramycin®)
    • 1 month prior to Visit 1: Topical prescription retinoids (e.g. Retin-A®, Retin-A Micro®, Renova®, Adapalene, Tazarotene, Avita®, Tazorac®, Avage®, Differin®), azelaic acid, benzoyl peroxide, dapsone, sodium sulfacetamide, Epiduo®, or other similar prescription drug on the face
    • 6 months prior to Visit 1: Accutane or other oral retinoid
    • 2 weeks prior to Visit 1: Any of the following on the face:

      • Light therapy
      • OTC topical medications/products (including antiacne or antibacterial agents, topical anti-inflammatories, topical retinoids, etc.). Sunscreens (SPF) are acceptable.
  5. Females who are pregnant, lactating, or planning to become pregnant during the study or within 30 days of study completion. (Subject must document her response in either the source documentation or /assent forms).
  6. Subject has a surgery and/or invasive medical procedure planned during the study.
  7. Subject has observable suntan, scars, nevi, tattoo, excessive hair (including beard, mustache, or goatee), or other dermal conditions on the face that that could interfere with study evaluations or confound study results, as determined by the PI or designee.
  8. Subject is taking medications that would mask an adverse event (AE) or influence the study results, including:

    • drugs and steroidal and/or non-steroidal anti-inflammatory drugs within 3 months before Visit 1 and during the study.
    • Regular use of antihistamines within 1 month before Visit 1 and during the study.
  9. Subject has a history of or a concurrent health condition/situation, which in the opinion of the PI, if medically qualified, or Study Physician, may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study.
  10. Subject is an employee/contractor or immediate family member of the PI, Study Site, or Sponsor.
  11. Subjects with unstable medical disorders.
  12. Subjects who are unwilling or unable to comply with the requirements of the protocol.
  13. Subjects with any known allergies or sensitivities to the study acne products.
  14. Subjects who are currently under the care of a dermatologist for acne.
  15. Subjects who are currently experiencing an acne flare.
  16. Subjects who have history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study.
  17. Subjects having started hormone replacement therapies (HRT) or hormones for birth control less than 3 months prior to the study entry or who plan on starting, stopping or changing doses of HRT or hormones for birth control during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Winlevi (clascoterone) 1% cream

    Drug: Winlevi (clascoterone) 1% cream

Interventions

06

What researchers measure

Primary outcomes

  1. The Primary Efficacy Endpoint is the Change in Causal Sebum Measurements From the Forehead Obtained With a Sebumeter During the Study.

    The values represents the mean change from baseline. Casual sebum level is measured using a Sebumeter by means of grease-spot photometry. In this method, the measuring head of a cassette probe briefly exposes a section of a mat tape and brings it into contact with the sebum present on the surface of the forehead. As the tape absorbs sebum, it becomes increasingly transparent; conversely, lower levels of sebum result in less transparency. After contact, the tape is inserted into the device, which determines its transparency using a photocell-based light transmission measurement. The amount of transmitted light-reported in units from 0 to 350 µg/cm²-corresponds to the level of sebum present on the skin surface. The measurement has an estimated uncertainty of ±5%.

    Time frame: Weeks 16

Secondary outcomes

  1. The Secondary Efficacy Endpoint is the Changes in the Facial Microbiome Induced by 12, and 52 Weeks of Clascoterone 1% Cream Application.

    Changes in the skin microbiome - specifically Cutibacterium acnes - were evaluated by swabbing each subject's forehead to obtain microbiological samples. The swab samples were treated with metapolyzyme to lyse cells, after which DNA was isolated and quantified. DNA sequencing was used to quantify Cutibacterium acnes as relative abundance, defined as the proportion of total bacterial sequencing reads attributable to C. acnes (range, 0-1). For each sample, the abundance score of C. acnes was converted to relative abundance, and descriptive statistics (mean, median, and standard deviation) were calculated across time points. Statistical significance between pairs of time points was assessed using a Wilcoxon rank-sum test, implemented within the ggpubr plotting framework.

    Time frame: Baseline, Week 12, and Week 52

07

Results

Posted Jun 15, 2026

Participant flow

Participant flow — Overall Study
MilestoneWinlevi (Clascoterone) 1% Cream
Started40
Completed39
Not completed1

Outcome measures

PrimaryThe Primary Efficacy Endpoint is the Change in Causal Sebum Measurements From the Forehead Obtained With a Sebumeter During the Study.

The values represents the mean change from baseline. Casual sebum level is measured using a Sebumeter by means of grease-spot photometry. In this method, the measuring head of a cassette probe briefly exposes a section of a mat tape and brings it into contact with the sebum present on the surface of the forehead. As the tape absorbs sebum, it becomes increasingly transparent; conversely, lower levels of sebum result in less transparency. After contact, the tape is inserted into the device, which determines its transparency using a photocell-based light transmission measurement. The amount of transmitted light-reported in units from 0 to 350 µg/cm²-corresponds to the level of sebum present on the skin surface. The measurement has an estimated uncertainty of ±5%.

Time frame:
Weeks 16
Reported as:
Mean · µg/cm²
The Primary Efficacy Endpoint is the Change in Causal Sebum Measurements From the Forehead Obtained With a Sebumeter During the Study.
µg/cm²Winlevi (Clascoterone) 1% Cream
The Primary Efficacy Endpoint is the Change in Causal Sebum Measurements From the Forehead Obtained With a Sebumeter During the Study.-27.33 ± 50.79
Statistical analysis
  • Winlevi (Clascoterone) 1% Cream · Wilcoxon signed rank test · p = 0.003
SecondaryThe Secondary Efficacy Endpoint is the Changes in the Facial Microbiome Induced by 12, and 52 Weeks of Clascoterone 1% Cream Application.

Changes in the skin microbiome - specifically Cutibacterium acnes - were evaluated by swabbing each subject's forehead to obtain microbiological samples. The swab samples were treated with metapolyzyme to lyse cells, after which DNA was isolated and quantified. DNA sequencing was used to quantify Cutibacterium acnes as relative abundance, defined as the proportion of total bacterial sequencing reads attributable to C. acnes (range, 0-1). For each sample, the abundance score of C. acnes was converted to relative abundance, and descriptive statistics (mean, median, and standard deviation) were calculated across time points. Statistical significance between pairs of time points was assessed using a Wilcoxon rank-sum test, implemented within the ggpubr plotting framework.

Time frame:
Baseline, Week 12, and Week 52
Reported as:
Median · Proportion relative to total
The Secondary Efficacy Endpoint is the Changes in the Facial Microbiome Induced by 12, and 52 Weeks of Clascoterone 1% Cream Application.
Proportion relative to totalWinlevi (Clascoterone) 1% Cream
Baseline0.606 (0.413 to 0.756)
Week 120.738 (0.360 to 0.866)
Week 520.797 (0.554 to 0.903)
Statistical analysis
  • Winlevi (Clascoterone) 1% Cream · Paired Wilcoxon Signed-Rank Tests (Two-S · p = 0.0609
  • Winlevi (Clascoterone) 1% Cream · Paired Wilcoxon Signed-Rank Tests (Two-S · p = 0.00433

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Winlevi (Clascoterone) 1% Cream0/40 (0%)0/40 (0%)1/40 (2.5%)
Most frequent other events
Most frequent other events
EventWinlevi (Clascoterone) 1% Cream
Mycoplasma pneumoniaRespiratory, thoracic and mediastinal disorders1/40

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Winlevi (Clascoterone) 1% Cream
<=18 years27
Between 18 and 65 years13
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Winlevi (Clascoterone) 1% Cream
Female23
Male17
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Winlevi (Clascoterone) 1% Cream
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander4
Black or African American11
White25
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Dermatology Consulting Services, PLLC
    High Point, North Carolina 27262, United States
09

References and documents

Publications

  • Draelos ZD, Kyeremateng K, Squittieri N. Reduction in Facial Sebum Production Following Treatment with Clascoterone Cream 1% in Patients with Acne Vulgaris: 12-Week Interim Analysis. Dermatol Ther (Heidelb). 2025 Sep;15(9):2657-2666. doi: 10.1007/s13555-025-01495-y. Epub 2025 Jul 19. PubMed 40682762 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Feb 2025, 11 months.

Results were first posted in Jun 2026, 1 year 4 months after primary completion.

Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 16, 2024
StartActual
Feb 14, 2024
Primary completionActual
Feb 12, 2025
CompletionActual
Feb 12, 2025
Results first posted
Jun 15, 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06415279
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Feb 14, 2024
Primary completion
Feb 12, 2025
Completion
Feb 12, 2025
Results posted
Jun 15, 2026
Last update
Jun 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion